Increased C-kit intensity is a poor prognostic factor for progression-free and overall survival in patients with newly diagnosed AML.

[1]  Gerhard Ehninger,et al.  Prevalence and prognostic impact of NPM1 mutations in 1485 adult patients with acute myeloid leukemia (AML). , 2006, Blood.

[2]  W. Tse,et al.  AF1q Is a Novel Poor Prognostic Marker for Adult Acute Myelogenous Leukemia (AML) Patients with Normal Cytogenetics. , 2005 .

[3]  A. Advani.  FLT3 and acute myelogenous leukemia: biology, clinical significance and therapeutic applications. , 2005, Current pharmaceutical design.

[4]  M. Graf,et al.  High expression of urokinase plasminogen activator receptor (UPA‐R) in acute myeloid leukemia (AML) is associated with worse prognosis , 2005, American journal of hematology.

[5]  J. Radich,et al.  Elevated expression of the AF1q gene, an MLL fusion partner, is an independent adverse prognostic factor in pediatric acute myeloid leukemia. , 2004, Blood.

[6]  A. Marx,et al.  Efficacy and safety of imatinib in adult patients with c-kit-positive acute myeloid leukemia. , 2004, Blood.

[7]  L. Rybicki,et al.  Timed-sequential chemotherapy with concomitant granulocyte colony-stimulating factor for newly diagnosed de novo acute myelogenous leukemia , 2003, Leukemia.

[8]  A. Marx,et al.  Sustained complete hematologic remission after administration of the tyrosine kinase inhibitor imatinib mesylate in a patient with refractory, secondary AML. , 2003, Blood.

[9]  A. Venditti,et al.  Amount of spontaneous apoptosis detected by Bax/Bcl-2 ratio predicts outcome in acute myeloid leukemia (AML). , 2003, Blood.

[10]  C. Bloomfield,et al.  Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.

[11]  V. Callea,et al.  Peripheral blood CD38 expression predicts survival in B-cell chronic lymphocytic leukemia. , 2001, Leukemia research.

[12]  Barbara Tripp,et al.  Chemotherapy for Acute Myelogenous Leukemia in the Elderly With Cytarabine, Mitoxantrone, and Granulocyte-Macrophage Colony-Stimulating Factor , 2001, American Journal of Clinical Oncology.

[13]  I. Weissman,et al.  Hematopoietic Stem Cells Need Two Signals to Prevent Apoptosis; Bcl-2 Can Provide One of These, Kitl/C-KIT Signaling the Other , 2000, The Journal of experimental medicine.

[14]  D. Linnekin,et al.  Early signaling pathways activated by c-Kit in hematopoietic cells. , 1999, The international journal of biochemistry & cell biology.

[15]  E. Thiel,et al.  Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia (AML), including cytogenetically good-risk AML, and lacks prognostic significance. , 1999, Leukemia & lymphoma.

[16]  L. Ashman,et al.  Expression of c-Kit and functional drug efflux are correlated in de novo acute myeloid leukaemia , 1997, Leukemia.

[17]  T. Suda,et al.  Soluble c‐kit molecule in serum from healthy individuals and patients with haemopoietic disorders , 1995, British journal of haematology.

[18]  M. Minden,et al.  c-KIT expression enhances the leukemogenic potential of 32D cells. , 1995, The Journal of clinical investigation.

[19]  R. Hoffman,et al.  Hematology: Basic Principles and Practice , 1995 .

[20]  M. Caligiuri,et al.  The c-kit ligand suppresses apoptosis of human natural killer cells through the upregulation of bcl-2. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[21]  I. Bernstein,et al.  Cell surface expression of c-kit receptors by childhood acute myeloid leukemia blasts is not of prognostic value: a report from the Childrens Cancer Group. , 1994, Blood.

[22]  M. Reuss-Borst,et al.  AML: immunophenotypic heterogeneity and prognostic significance of c-kit expression. , 1994, Leukemia.

[23]  J. Schlessinger,et al.  Modulation of p145c-kit function in cells of patients with acute myeloblastic leukemia. , 1993, Cancer research.

[24]  H. Kitayama,et al.  Expression and functional role of the proto-oncogene c-kit in acute myeloblastic leukemia cells. , 1991, Blood.

[25]  H. Polk,et al.  HLA-DR antigen expression on peripheral blood monocytes correlates with surgical infection. , 1991, American journal of surgery.

[26]  L. Ashman,et al.  Monoclonal antibody YB5.B8 identifies the human c-kit protein product , 1991 .

[27]  S. Lev,et al.  A specific combination of substrates is involved in signal transduction by the kit‐encoded receptor. , 1991, The EMBO journal.

[28]  M. Minden,et al.  The expression of the proto-oncogene C-kit in the blast cells of acute myeloblastic leukemia. , 1989, Leukemia.

[29]  C. Juttner,et al.  Expression of a 150-kD cell surface antigen identified by monoclonal antibody YB5.B8 is associated with poor prognosis in acute non-lymphoblastic leukaemia. , 1988, Leukemia research.

[30]  A. Ullrich,et al.  Human proto‐oncogene c‐kit: a new cell surface receptor tyrosine kinase for an unidentified ligand. , 1987, The EMBO journal.